New Therapies Approved for Multiple Myeloma
The FDA approved panobinostat, ixazomib, elotuzumab, and daratumumab for relapsed multiple myeloma in 2015
Multiple myeloma (MM) is a malignant plasma cell disorder that accounts for about 1% of all cancers. Over the last decade, several pharmacologic agents—including proteasome inhibitors, immunomodulatory drugs, and novel monoclonal antibodies—have been approved, markedly improving patient outcomes. In 2015, the FDA approved four novel agents—panobinostat, ixazomib, elotuzumab, and daratumumab—for the treatment of relapsed MM, potentially offering the hope of improved survival.
These approvals represent a significant advance in therapeutic options for patients with relapsed and refractory multiple myeloma, expanding choices that can improve progression‑free and overall survival.
Bizonyítékszint: Irányelv / elfogadott gyakorlat. Magas szintű klinikai elfogadottság.
Kapcsolódó jelek
- Multiple Myeloma Clinical Trials & Emerging Therapies
- A single‑cell atlas of multiple myeloma defines malignant archetypes and proliferative states
- S2209: Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM)
- Improved survival in multiple myeloma following prior detection of precursor conditions: a nationwide real-world study
- Nanomedicine-Empowered CAR‑T Therapy for Multiple Myeloma: Toward Programmable, Durable, and Precision Immunotherapy